

PRIOR AUTHORIZATION POLICY

POLICY: Complement System Disorders – WHIM Syndrome – Xolremdi Prior Authorization Policy

- Xolremdi™ (mavoxafor capsules – X4 Pharmaceuticals)

REVIEW DATE: 05/08/2024

OVERVIEW

Xolremdi, a CXC chemokine receptor 4 (CXCR4) antagonist, is indicated for the treatment of **WHIM syndrome** (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes in adults and children ≥ 12 years of age.¹

Disease Overview

WHIM syndrome is a rare autosomal primary immunodeficiency that causes hyperactivity with failure to down regulate the CXCR4 receptor.^{2,3} Most of the patients with WHIM syndrome are heterozygous carriers of mutations of CXCR4. Clinical presentation include recurrent bacterial infections and severe or chronic neutropenia that begins in infancy or early childhood. There is no cure for WHIM syndrome and prior to the approval of Xolremdi, treatment was based on patient's symptoms.²

Clinical Efficacy

The efficacy of Xolremdi for the treatment of WHIM syndrome has been evaluated in one pivotal study.^{1,4} The study included patients ≥ 12 years of age with genetically confirmed WHIM syndrome and confirmed absolute neutrophil count (ANC) ≤ 400 cells/ μ L or white blood cells (WBC) ≤ 400 cells/ μ L. The primary efficacy endpoint of the meantime above threshold ANC (TAT-ANC) at Week 52 assessment.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Xolremdi. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Xolremdi as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Xolremdi to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Xolremdi is recommended in those who meet the following criteria:

FDA-Approved Indication

1. **WHIM syndrome.** Approve Xolremdi for the duration noted if the patient meets ONE of the following (A or B):

- A) **Initial Therapy.** Approve for 1 year if the patient meets ALL of the following (i, ii, iii, and iv):
 - i. Patient is ≥ 12 years of age; AND
 - ii. Genetic testing confirms pathogenic and or likely pathogenic variants in the CXCR4 gene; AND
 - iii. Patient meets ONE of the following (a or b):
 - a) At baseline, patient had an absolute neutrophil count ≤ 400 cells/ μ L; OR
 - b) At baseline, patient had a white blood cell count ≤ 400 cells/ μ L; AND
 - iv. The medication is prescribed by or in consultation with an immunologist, hematologist or dermatologist.
- B) **Patient is Currently Receiving Xolremdi.** Approve for 1 year if, according to the prescriber, the patient is continuing to derive benefit from Xolremdi as determined by the most recent objective measurement.

Note: Examples of objective measurements of a response to Xolremdi therapy are reduced frequency, duration, or severity of infections, less frequent treatment with antibiotics, fewer warts, or improved or stabilized clinical signs/symptoms of WHIM syndrome (e.g., absolute neutrophil count, white blood cell count, and absolute lymphocyte count).

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Xolremdi is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Xolremdi™ oral capsules [prescribing information]. Boston, MA: X4 Pharmaceuticals; April 2024.
2. Kawai T and Malech HL. WHIM syndrome: congenital immune deficiency disease. *Curr Opin Hematol.* 2009;16(1):20-26.
3. Heusinkveld LE, Yim E, Yant A, et al. Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency. *Expert Opin Orphan Drugs.* 2017;5(10):813-825.
4. Badolato R, Donadieu J, and 4WHIM Study Group. Results of a phase 3 Trial of an oral CXCR4 antagonist, mavoxixafor, for treatment of patients with WHIM syndrome. Presented at: Clinical Immunology Society Annual Meeting and European Hematology Association Annual Congress; *Clin Immun.* 2023;250S.